Skip to content

Bicara Therapeutics BCAX Operating Income

Operating Income at other companies

Amgen logo
AmgenAMGN
$2.67B+126%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$46.11M+30.9%
Immunome logo
ImmunomeIMNM
-$59.33M-32.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$134M-9.8%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$34.2M+59.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$116.17M-23.8%

Segments

By segment

See full
Reportable Segment-$60.24M-44.2%

Other financials

Income statement

See full
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.64B+81.4%
Enterprise value$1.32B+288%

Returns & leverage

See full
Return on equity-32.3%
Debt / equity0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's operating income?
Bicara Therapeutics (BCAX) reported operating income of -$60.24M in Q1 2026.
How has Bicara Therapeutics's operating income changed year-over-year?
Bicara Therapeutics's operating income decreased by 44.2% year-over-year, from -$41.79M to -$60.24M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.